A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls
Latest Information Update: 13 Mar 2024
Price :
$35 *
At a glance
- Drugs Viltolarsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors NS Pharma
- 10 Mar 2024 Status changed from recruiting to completed.
- 16 Mar 2023 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 02 Sep 2021 New trial record